Growing potential for umbilical cord stem cells

Exciting development is to develop opportunities for umbilical cord stem cells, in accordance with article, published in November 2009, the opinion of an expert in biological therapy. This article discusses the development of carlecortemcel-l (brand of StemEx), strains of umbilical cord blood stem cells created by encouraging the proliferation of stem cells – without allowing to distinguish.

What does this mean and why is it important?

Although there is much evidence of the healing potential of stem cells extracted from the umbilical cord blood, it was claimed that a limited number of stem cells available from one unit of the banked is not sufficient for the treatment of patients other than children or adults is very small. Creating a method of multiplying these stem cells in their vital State of a pre-differentiated, researchers may potentially face this challenge and widen the application of multiple stem cell treatments.

The results of the phase I study carlecortemcel-l performed at the University of Texas m. d. Anderson Cancer Center reported in the article, suggest that the surcharges these stem cells enlarged umbilical cord is safe – and may be beneficial for adults and adolescents with leukemia and Lymphoma. The continuation phase II/III safety and efficacy studies named Are now registering youth and adults with a high risk of hematologic malignancies in clinical trials in the United States, Italy, Spain, Hungary and Israel. Gamida cell and Teva Pharmaceuticals, co-developers StemEx, predict the product officially reaching cabinets 2011.

Be the first to like this post.Tags: stem cells

This entry was posted on 15 October 2009 at 12: 00 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us

Cancer Center expands opportunities for stem cells cord blood

Happy to report another step on the road to blood, umbilical cord!  This month, Fred Hutchinson Cancer Center in Seattle, Washington announced that have been successfully treating leukemia with the aid of blood, umbilical cord that has been manipulated in the laboratory to increase the number of useful stem cells.  The results of the phase I study Center have been published in the January 2010 issue of Nature Medicine.

The Problem inherent with using Cord Blood in the treatment of leukemia injection is a relatively small number of stem cells in the standard cord blood samples; Therefore, to date, has the greatest potential of Cord Blood has been limited to children or small adults.  The ability to expand the number of stem cells in Cord Blood, however, comes the expanded treatment options in the greater part of the population.

Results from studies Hutch 10 Leukemia patients show that aid blood stem cells extended the cord is not only safe, but also effectively cut the time to engraftment by half compared to the stem cells of the blood-manipulate the cord.  Motto: faster engraftment takes place, the better a patient's chance of survival.   Seven study 10 patients are still alive today and show no signs of disease.

Cord blood is still a promising alternative to bone marrow transplant, are less susceptible to "graft vs. host disease and other complications for the recipient of the rejection of foreign cells, and do not require a perfect donor.  In the previous blog entry, we reported on a similar process extension cord blood stem cell population, using the carlecortemcel-l (aka StemEx), published by the University of Texas m. d. Anderson Cancer Center in Houston.  While the need for supplementary studies in order to fully realise the results of constant news of these events is encouraging and exciting – both to us at NECBB, and for families, have Blood cord in the future.

Be the first to like this post.Tags: engraftment, studies of human leukemia

This entry was posted on January 13, 2010 at 7: 22 pm and is filed under the cord blood research. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us

Reprogramming stem cells cord blood

Induced pluripotent stem cells (iPSCs) have been in the news a bit late, especially with the report on Chinese summer two studies indicating that stem cells created from adult mouse skin cells have the ability to regenerate in a similar way as embryonic stem cells obtained in both cases in the birth of a baby mouse.

It look like the cord blood cells can be determined in a similar way as adult stem cells in these tests is, but with a smaller number of factors and in less time, according to Juan Carlos Izpisúa Belmonte, Ph.d., a professor in the laboratory of expression of the gene Institute Salk, who led his own study published in the October journal stem cells cells.

This accepts the message, some wind from sails one argument against using his own stem cells in cord blood of Maldives to treat diseases: that stem cells may contain the same genetic mutation or suffer a mutation that caused the disease in the first place. Reprogramming stem cells cord blood, however, researchers may potentially remove the capabilities of this ever happening.

Be the first to like this post.Tags: animals, iPSCs

This entry was posted on October 2, 2009 at 4: 30 pm and is filed under the cord blood tests, Uncategorized. You can track any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback your own site.

cord blood us

Umbilical Cord Blood MSC Cells Shown to Inhibit Breast Cancer Growth, What Else?

Umbilical cord mesenchymal stem cells (MSCs) have been shown to inhibit breast cancer cell growth but it is not known whether this effect is specific to only breast cancer cells. Investigators compared the effects of human Wharton’s jelly stem cell (hWJSC) extracts [conditioned medium (hWJSC-CM) and cell lysate (hWJSC-CL)] on breast adenocarcinoma, ovarian carcinoma and osteosarcoma cells. The cells were treated with either hWJSC-CM (50%) or hWJSC-CL (15µg/ml) for 48 hours – 72 hours and changes in cell morphology, proliferation, cycle, gene expression, migration and cell death studied. All three cancer cell lines showed cell shrinkage, blebbing and vacuolations with hWJSC-CL and hWJSC-CM compared to controls.  MTT and BrdU assays showed inhibition of cell growth by 2%-6% and 30%-60% while Transwell migration assay showed inhibition by 20%-26% and 31%-46% for hWJSC-CM and hWJSC-CL respectively for all three cancer cell lines.

New Study Shows Cord Blood Stem Cells May Treat Type 1 Diabetes

A newly published clinical trial result reports treating Type 1 diabetics T-Cells with umbilical cord blood stem cells helped restart pancreatic function and insulin production.  The process is called “re-education” as the newly introduced T-Cells improved the behavior of the patients own T-Cells.

The study recruited 15 Type 1 diabetic patients, twelve of which had the treatment with three in the control group.  In the study the 12 participants had their T-Cells – which had been separated from their blood – pumped into a device named the “stem cell educator”.  There the patients stem cells were exposed to the cord blood stem cells for three hours.  Then the stem cells are pumped back into the participants’ blood.

The study showed that the patients who could not create their own insulin prior to the treatment were able to create insulin after the treatment.  One year after the study those patients who received the treatment continued to manufacture some of their own insulin with eight of the patients reducing insulin usage by 38%.